Professor Sumit Chanda is an infectious disease expert and immunologist, where he works both in the Department of Immunology and Microbiology and at Calibr, Scripps Research’s nonprofit drug discovery and development division. He has devoted his career to understanding how the immune system responds to numerous viruses, such as influenza, Dengue virus and SARS-CoV-2. Listen as we discuss everything from pandemic preparedness to drug discovery, as well as his unrelenting drive to uncover new treatment options—including for COVID-19.

Episode transcript
https://www.scripps.edu/_files/images/2023_images/sumit-chanda-transcript.pdf

Infectious disease sleuth Sumit Chanda, PhD, joins Scripps Research and its Calibr drug discovery division
https://www.scripps.edu/news-and-events/press-room/2021/20210915-chanda-calibr.html 

Center for Antiviral Medicines & Pandemic Preparedness
https://www.campp.org/ 

Chanda lab website
https://linktr.ee/thechandalab 

Twitter/Instagram
@thechandalab

Episode 40 – Sumit Chanda: How can we prepare for the next pandemic?

Histophilus somni: Biology, Molecular Basis of Pathogenesis, and Host Immunity (Current Topics in Microbiology and Immunology, 396)

Read Book : https://centerofsound.blogspot.com/?oak=3319295543

This volume reviews the current understanding of the taxonomy, disease syndromes, genetics, biology, and pathogenic factors of Histophilus somni, as well as the host immune response to this pathogen. H. somni is one of the most important bacterial pathogens in cattle and other ruminants, and its virulence factors are highly conserved with Haemophilus influenzae and other members of the Pasteurellaceae. H. somni has been recognized as a major cause of thrombotic meningoencephalitis, respiratory disease syndromes, myocarditis, reproductive disease syndromes, polyarthritis, mastitis, ocular disease, and septicemia. The only known habitats of H. somni are the mucosal surfaces of ruminants, making this bacterium an opportunistic pathogen. Although it is capable of causing inflammation at systemic

PDF Histophilus somni: Biology, Molecular Basis of Pathogenesis, and Host Immuni

Welcome to the tenth episode of YJBM Science News, where we discuss the recent news in healthcare and science across the Yale community. Today, our hosts Mara and Samantha discuss four of the most intriguing topics of the past week.

Links:
https://doi.org/10.1016/j.immuni.2024.01.005
https://doi.org/10.1016/j.jpain.2023.11.019
https://doi.org/10.1073/pnas.2314699121

YJBM Science News Podcast: Episode 10

More than 90% of drugs fail to make it from the lab bench to approval. How, then, has a physician-scientist like Hugh Rosen found so much success in developing medicines? Rosen, who’s the chair of molecular and cellular biology at Scripps Research, co-invented the drugs ozanimod (approved for multiple sclerosis and ulcerative colitis) and navacaprant (in Phase 3 trials for major depressive disorder).  

In this episode of Science Changing Life, listen in as Rosen unveils the success stories behind these groundbreaking treatments—shedding light on the challenges and triumphs shaping modern medicine.

Rosen Lab: https://www.scripps.edu/rosen/index.html  
Scripps Research Magazine: magazine.scripps.edu/

A physician-scientist’s guide to developing medicines

The award-winning Science Changing Life podcast offers an inside look into how Scripps Research scientists are solving the most pressing mysteries in human health and disease. Join hosts Lauren Fish and Melissa Suran, PhD, as they speak with world-class scientists at the forefronts of immunology, infectious disease, artificial intelligence, personalized medicine, neuroscience and much more. 

Science Changing Life gives listeners a glimpse into the people behind the science, their motivations, paths to discovery, and how they’re changing the world. 

Follow us on social media for more updates:
@scrippsresearch on Twitter and Instagram
@ScrippsResearchInstitute on Facebook
Scripps Research on LinkedIn

New tracks tagged #immunology,